Overview and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI01 for an undetermined period of time and are prioritizing LTI03. Our pipeline includes: LTI-03, a peptide, for...
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126385 | EDGAR | 98K words |
| 2025-04-07 | 2024-12-31 | 0000950170-25-051566 | EDGAR | — |
| 2024-04-15 | 2023-12-31 | 0000950170-24-044508 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0000950170-23-008767 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004774 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001564590-21-015115 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001564590-20-014155 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001564590-19-010007 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001564590-18-007403 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281622 | EDGAR | 31K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108836 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072607 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127019 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097199 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060583 | EDGAR | — |
| 2023-10-13 | 2023-09-30 | 0000950170-23-053302 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041839 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018476 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000950170-22-020709 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017372 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007793 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001193125-26-084012 | EDGAR | 15K words |
| 2026-02-19 | 0001193125-26-059545 | EDGAR | — |
| 2026-01-16 | 0001193125-26-015524 | EDGAR | — |
| 2025-12-11 | 0001193125-25-316225 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261706 | EDGAR | — |
| 2025-10-24 | 0001193125-25-250175 | EDGAR | — |
| 2025-10-09 | 0001193125-25-235152 | EDGAR | — |
| 2025-09-22 | 0001193125-25-210050 | EDGAR | — |
| 2025-09-09 | 0001193125-25-198816 | EDGAR | — |
| 2025-08-19 | 0001193125-25-183073 | EDGAR | — |
160 total filings indexed. 129 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001420565 |
| Ticker | RNTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.reintx.com |
| Listed | 2017-06-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report